Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (HKG:9989)

Hong Kong · Delayed Price · Currency is HKD

4.095

-0.060 (-1.44%)

Sep 16, 2026, 1:50 PM HKT

Market Cap	14.58B -22.6%
Revenue (ttm)	6.05B -0.4%
Net Income	234.27M -49.9%
EPS	0.16 -49.9%
Shares Out	n/a
PE Ratio	62.24
Forward PE	n/a
Dividend	0.17 (4.00%)
Ex-Dividend Date	May 27, 2026

Volume	74,000
Open	4.095
Previous Close	4.155
Day's Range	4.070 - 4.120
52-Week Range	3.740 - 5.980
Beta	0.27
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 28, 2026

About HKG:9989

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. provides pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally. It operates in four segments: Pharmaceutical preparations, Active Pharmaceutical Ingredients (API), Contract Development and Manufacturing Organization (CDMO), and Others. The company offers pharmaceutical preparations products, such as enoxaparin sodium injection; API products, including heparin and enoxaparin sodium APIs. It also provides molecule biologics CDMO services, which include... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1998

Employees 2,150

Stock Exchange Hong Kong Stock Exchange

Ticker Symbol 9989

Financial Performance

In 2025, HKG:9989's revenue was 5.48 billion, an increase of 3.75% compared to the previous year's 5.28 billion. Earnings were 349.49 million, a decrease of -45.96%.

Financial numbers in CNY Financial Statements